Galimedix Reports Promising Data for Alzheimer's Treatment

Galimedix Therapeutics has presented new data on GAL-201, an oral treatment candidate for Alzheimer's disease (AD), at the AD/PD™ 2025 conference in Vienna. The data highlights GAL-201's ability to bind to misfolded amyloid-β (Aβ) monomers, preventing their aggregation into toxic oligomers and improving synaptic plasticity.

GAL-201 has shown potential in reducing Aβ plaques, a marker of AD, and demonstrates anti-inflammatory effects on central nervous system cells. The compound's impact on synaptic function and neuroinflammation suggests it might prevent cognitive decline, maintaining functionality even at low concentrations due to its long-lasting effect.

Currently in Phase 1 trials, GAL-201 is positioned as a promising oral candidate for AD, combining high selectivity and potency in modulating Aβ aggregation.